Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer

To explore the efficacy and safety of paclitaxel+oxaliplatin+S-1 (PSOX), docetaxel+oxaliplatin+fluorouracil (DOF) and oxaliplatin+S-1 (SOX) regimens as neoadjuvant chemotherapy for advanced gastric cancer (GC). A retrospective analysis was used in 306 patients with GC who underwent neoadjuvant chemo...

Full description

Saved in:
Bibliographic Details
Published inFuture oncology (London, England) Vol. 18; no. 40; pp. 4483 - 4492
Main Authors Yu, Pengjie, Zhu, Shengmao, Pu, Yongqiang, Cai, Baojia, Ma, Xiaoming, Zhang, Chengwu
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To explore the efficacy and safety of paclitaxel+oxaliplatin+S-1 (PSOX), docetaxel+oxaliplatin+fluorouracil (DOF) and oxaliplatin+S-1 (SOX) regimens as neoadjuvant chemotherapy for advanced gastric cancer (GC). A retrospective analysis was used in 306 patients with GC who underwent neoadjuvant chemotherapy, consisting of 102 from the PSOX group, 100 from the DOF group and 104 from the SOX group. The total effective rates and disease control rates for the PSOX, DOF and SOX groups were 31.4, 18 and 16.3% and 96.1, 94 and 92.3%, respectively. The highest total effective rate and disease control rate were found in the PSOX groups. Moreover, no difference among the PSOX, DOF and SOX groups on the incidence of adverse events was observed (p > 0.05). The PSOX regimen is an alternative neoadjuvant chemotherapy regimen for GC patients.
AbstractList To explore the efficacy and safety of paclitaxel+oxaliplatin+S-1 (PSOX), docetaxel+oxaliplatin+fluorouracil (DOF) and oxaliplatin+S-1 (SOX) regimens as neoadjuvant chemotherapy for advanced gastric cancer (GC). A retrospective analysis was used in 306 patients with GC who underwent neoadjuvant chemotherapy, consisting of 102 from the PSOX group, 100 from the DOF group and 104 from the SOX group. The total effective rates and disease control rates for the PSOX, DOF and SOX groups were 31.4, 18 and 16.3% and 96.1, 94 and 92.3%, respectively. The highest total effective rate and disease control rate were found in the PSOX groups. Moreover, no difference among the PSOX, DOF and SOX groups on the incidence of adverse events was observed (p > 0.05). The PSOX regimen is an alternative neoadjuvant chemotherapy regimen for GC patients.
Author Ma, Xiaoming
Pu, Yongqiang
Zhu, Shengmao
Yu, Pengjie
Zhang, Chengwu
Cai, Baojia
AuthorAffiliation 1Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
AuthorAffiliation_xml – name: 1Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
Author_xml – sequence: 1
  givenname: Pengjie
  orcidid: 0000-0003-4445-2888
  surname: Yu
  fullname: Yu, Pengjie
  organization: Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
– sequence: 2
  givenname: Shengmao
  surname: Zhu
  fullname: Zhu, Shengmao
  organization: Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
– sequence: 3
  givenname: Yongqiang
  surname: Pu
  fullname: Pu, Yongqiang
  organization: Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
– sequence: 4
  givenname: Baojia
  surname: Cai
  fullname: Cai, Baojia
  organization: Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
– sequence: 5
  givenname: Xiaoming
  surname: Ma
  fullname: Ma, Xiaoming
  organization: Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
– sequence: 6
  givenname: Chengwu
  surname: Zhang
  fullname: Zhang, Chengwu
  organization: Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, 810000, Qinghai, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36916454$$D View this record in MEDLINE/PubMed
BookMark eNp1kEuLFDEURoOMOA9dupUsXViaZz2WMg8VBlpQwV1I3dzMZOhK2iQ10P_etD26EwLJF04-bs45OYkpIiGvOXsvBB8--BQ7wYTomJTDM3LGB6W6UTJ-0s5qmLq-n9QpOS_lgTE1SM1ekFPZT7xXWp2Reu19AAt7aqOjxXqse4qPdrvaGlKkydOv3zY_39Grzc0fpAWa8S4sGAu1hUZM1j2sjzZWCve4pHqP2e721KdMrWv3gI7e2VJzAAqHmF-S595uC7562i_Ij5vr75efu9vNpy-XH287kErWbhYCJm2F57ItB77vNcyaS5B88M4z7YGNEkcLfhaACrnWyjo7uEmBmuUFeXvs3eX0a8VSzRIK4HZr29RrMWIY-5GLUeiGdkcUcioloze7HBab94YzcxBtmmhzEG0Oohv_5ql6nRd0_-i_ZhswHQG_1jVjgYDt6-aY2osAIeJ_yn8DmzCP6Q
CitedBy_id crossref_primary_10_1002_cam4_5977
Cites_doi 10.4251/wjgo.v11.i9.652
10.1177/1010428317714626
10.1016/S0140-6736(18)32557-1
10.1007/s10637-010-9507-2
10.1186/s12885-018-4615-z
10.1007/s00280-012-2066-9
10.1002/ijc.29210
10.1007/s10120-018-0884-0
10.4251/wjgo.v12.i1.37
10.3322/caac.21492
10.1016/bs.podrm.2018.11.001
10.1111/cas.14586
10.1186/s12885-020-07764-7
ContentType Journal Article
Copyright 2023 Future Medicine Ltd
Copyright_xml – notice: 2023 Future Medicine Ltd
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.2217/fon-2022-0337
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1744-8301
EndPage 4492
ExternalDocumentID 10_2217_fon_2022_0337
36916454
Genre Journal Article
GroupedDBID ---
0R~
29H
4.4
53G
5GY
70G
7X7
8AO
AAWTL
ABJNI
ACGFS
ACWKX
ADBBV
AENEX
AFFYO
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CS3
DU5
EBS
F5P
HZ~
IAO
IEA
IHR
K-O
MV1
NTCAX
O9-
P2P
PQQKQ
PROAC
RFM
TFL
3V.
88E
8FI
8FJ
ABUWG
ALIPV
CCPQU
CGR
CUY
CVF
ECM
EHMNL
EIF
EJD
FYUFA
H13
HMCUK
ITC
M1P
M4Z
NPM
OVD
PSQYO
RPM
TDBHL
TEORI
TFMDE
TMEDX
UKHRP
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c343t-b22c95a2f13f13dcf665cb513c317fdf05fc083e8acfb2ce4e1554ada7d94c4b3
ISSN 1479-6694
IngestDate Fri Oct 25 11:42:52 EDT 2024
Fri Dec 06 09:35:47 EST 2024
Sat Sep 28 08:17:17 EDT 2024
Fri May 10 00:16:09 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 40
Keywords neoadjuvant chemotherapy
PSOX
advanced gastric cancer
safety
efficacy
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c343t-b22c95a2f13f13dcf665cb513c317fdf05fc083e8acfb2ce4e1554ada7d94c4b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4445-2888
PMID 36916454
PQID 2786812825
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2786812825
crossref_primary_10_2217_fon_2022_0337
pubmed_primary_36916454
futurescience_futuremedicine_10_2217_fon_2022_0337
PublicationCentury 2000
PublicationDate 2022-12-01
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Future oncology (London, England)
PublicationTitleAlternate Future Oncol
PublicationYear 2022
Publisher Future Medicine Ltd
Publisher_xml – name: Future Medicine Ltd
References e_1_3_4_4_1
Li T (e_1_3_4_14_1) 2011; 14
e_1_3_4_3_1
Zhang X (e_1_3_4_16_1) 2020; 12
e_1_3_4_9_1
e_1_3_4_8_1
e_1_3_4_7_1
e_1_3_4_6_1
e_1_3_4_5_1
e_1_3_4_12_1
e_1_3_4_13_1
e_1_3_4_10_1
e_1_3_4_11_1
e_1_3_4_17_1
e_1_3_4_15_1
References_xml – ident: e_1_3_4_9_1
  doi: 10.4251/wjgo.v11.i9.652
– ident: e_1_3_4_5_1
  doi: 10.1177/1010428317714626
– ident: e_1_3_4_11_1
  doi: 10.1016/S0140-6736(18)32557-1
– ident: e_1_3_4_13_1
  doi: 10.1007/s10637-010-9507-2
– ident: e_1_3_4_17_1
  doi: 10.1186/s12885-018-4615-z
– ident: e_1_3_4_7_1
  doi: 10.1007/s00280-012-2066-9
– ident: e_1_3_4_4_1
  doi: 10.1002/ijc.29210
– ident: e_1_3_4_10_1
  doi: 10.1007/s10120-018-0884-0
– ident: e_1_3_4_12_1
  doi: 10.4251/wjgo.v12.i1.37
– volume: 12
  start-page: 6641
  year: 2020
  ident: e_1_3_4_16_1
  article-title: Comparison of docetaxel + oxaliplatin + S-1 vs oxalipatin + S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer: a propensity score matched analysis.
  publication-title: Cancer Managt. Rest.
  contributor:
    fullname: Zhang X
– volume: 14
  start-page: 104
  issue: 2
  year: 2011
  ident: e_1_3_4_14_1
  article-title: Efficacy and safety of SOX regimen in advanced gastric cancer.
  publication-title: Chin. J. Gastrointest. Surg.
  contributor:
    fullname: Li T
– ident: e_1_3_4_3_1
  doi: 10.3322/caac.21492
– ident: e_1_3_4_6_1
  doi: 10.1016/bs.podrm.2018.11.001
– ident: e_1_3_4_8_1
  doi: 10.1111/cas.14586
– ident: e_1_3_4_15_1
  doi: 10.1186/s12885-020-07764-7
SSID ssj0047350
Score 2.3789196
Snippet To explore the efficacy and safety of paclitaxel+oxaliplatin+S-1 (PSOX), docetaxel+oxaliplatin+fluorouracil (DOF) and oxaliplatin+S-1 (SOX) regimens as...
SourceID proquest
crossref
pubmed
futurescience
SourceType Aggregation Database
Index Database
Publisher
StartPage 4483
SubjectTerms advanced gastric cancer
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Docetaxel - adverse effects
efficacy
Humans
neoadjuvant chemotherapy
Neoadjuvant Therapy
Oxaliplatin - adverse effects
Paclitaxel - adverse effects
PSOX
Retrospective Studies
safety
Stomach Neoplasms - drug therapy
Stomach Neoplasms - etiology
Title Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer
URI http://dx.doi.org/10.2217/fon-2022-0337
https://www.ncbi.nlm.nih.gov/pubmed/36916454
https://search.proquest.com/docview/2786812825
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVZB6Uwxr6XfaHB2EvmLZZkx34co6UMujy0hXQvRpalNIHY_bBf9ro_vnsly3G2BLZBELEcR-BzuL6Sjs8l5F0c6hR9PgKN2kEBD6AgLXgY5JMkFZEaKy5xHfLkW3x8Lr7Ootlg8LOnWmrq_KP6sfW9kv9BFfoAV3xL9h-Q7f4UOuA74AstIAztX2F8iP4PWK_drn5Lg_LLtX23lbedTmc2rEyPnEhzOhthLYYVzF6xxEypK1ksG0in6xHAt2rfx3Iqzk4fMJdY3UOhQky1al5f2dNakoyqUjkvp20FQnqLDReN0wSX8-WiY9T3S9t7egndK1l1wdr2XlTl_BooPF9vlizcPkm1XMj-mgVjPf2HdnF2IkSQ8Lbvj0DceBOnNqzCHJJvi_eMWZMoU5WBHWbMnYNMD_urlQWfx5AHC-dX_ZvBtj91h9xFN0Xhl3zc4xxLM4-dOSuO9mljrAOy76_eyGvuOUOYNonZPXmxSczZA3K_nX3Qz45KD8lAl4_I_kmrr3hMas8oCrhRxyi6ZhStDEVGfaDAJ_sTOKCeT1Te0h6faJ9PFPhEPZ9oyyfq-PSEnB8dnn05Dtq6HIHigtdBzphKI8lMyOFTKBPHkcqjkCtIRk1hxpFRkNnrRCqTM6WFxqRVFnJSpEKJnD8le2VV6ueEponGnek8hFYkrJCAgImYyYsEiw8lQ_Le39XsytmvZDBtRSQyQCJDJDJEYkjYxj3P3JEXqOy66K0HJoOoiltlEu5Tc5uxSYLGfAmLhuSZQ6wb3yP-YueZl-RgzfpXZK--afRryF3r_I3l1i-cVZkI
link.rule.ids 314,780,784,27924,27925
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+evaluation+of+PSOX%2C+DOF+and+SOX+regimens+as+neoadjuvant+chemotherapy+for+advanced+gastric+cancer&rft.jtitle=Future+oncology+%28London%2C+England%29&rft.au=Yu%2C+Pengjie&rft.au=Zhu%2C+Shengmao&rft.au=Pu%2C+Yongqiang&rft.au=Cai%2C+Baojia&rft.date=2022-12-01&rft.eissn=1744-8301&rft.volume=18&rft.issue=40&rft.spage=4483&rft_id=info:doi/10.2217%2Ffon-2022-0337&rft_id=info%3Apmid%2F36916454&rft.externalDocID=36916454
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-6694&client=summon